Related references
Note: Only part of the references are listed.Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction
Emanuela Marcenaro et al.
BLOOD (2009)
Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Hiroyuki Fujisaki et al.
CANCER RESEARCH (2009)
Natural Killer Cell Accumulation in Tumors Is Dependent on IFN-γ and CXCR3 Ligands
Marco Wendel et al.
CANCER RESEARCH (2008)
Establishment and characterization of a cell based artificial antigen-presenting cell for expansion and activation of CD8+ T cells Ex Vivo
Weijuan Gong et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2008)
Natural killer cell-directed therapies: moving from unexpected results to successful strategies
Magali Terme et al.
NATURE IMMUNOLOGY (2008)
NKG2D ligands in tumor immunity
N. Nausch et al.
ONCOGENE (2008)
The NKG2D receptor: sensing stressed cells
Carlos Lopez-Larrea et al.
TRENDS IN MOLECULAR MEDICINE (2008)
The NKG2D receptor: immunobiology and clinical implications
Steven J. Burgess et al.
IMMUNOLOGIC RESEARCH (2008)
NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway
Tiffany Horng et al.
NATURE IMMUNOLOGY (2007)
ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15
Claire L. Sutherland et al.
BLOOD (2006)
IL-15/IL-15 receptor biology: A guided tour through an expanding universe
Vadirn Budagian et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2006)
Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance
DE Oppenheim et al.
NATURE IMMUNOLOGY (2005)
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
C Imai et al.
BLOOD (2005)
Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells
JD Coudert et al.
BLOOD (2005)
Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors
P André et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Role of 4-1BB:4-1BB ligand in cancer immunotherapy
ATC Cheuk et al.
CANCER GENE THERAPY (2004)
CD107a as a functional marker for the identification of natural killer cell activity
G Alter et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma
ES Doubrovina et al.
JOURNAL OF IMMUNOLOGY (2003)
New directions in natural killer cell-based immunotherapy of human cancer
SS Farag et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2003)
Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction
GM Spaggiari et al.
BLOOD (2002)
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
V Groh et al.
NATURE (2002)
Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: evidence for a negative regulation exerted by members of the inhibitory receptor superfamily
GM Spaggiari et al.
BLOOD (2002)
Cutting edge: NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment
AI Roberts et al.
JOURNAL OF IMMUNOLOGY (2001)
A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells
S Carlens et al.
HUMAN IMMUNOLOGY (2001)
Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo
A Cerwenka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
